The New England Journal of MedicineUltrasound Blood–Brain Barrier Opening and Aducanumab in Alzheimer’s Disease

Enhanced Amyloid Clearance in Alzheimer’s: Focused Ultrasound and Aducanumab’s Synergistic Potential

In a groundbreaking clinical trial, researchers have explored the combined use of focused ultrasound and the antiamyloid antibody aducanumab to enhance amyloid-beta clearance in the brain of Alzheimer’s patients. This innovative approach seeks to address the challenge of delivering therapeutic agents across the blood-brain barrier, a significant obstacle in Alzheimer’s disease treatment. By applying focused ultrasound in conjunction with aducanumab infusions, the study offers promising insights into potentially more effective treatments for Alzheimer’s, marking a significant step in the fight against this debilitating condition.

Key Points:

• The trial involved using focused ultrasound with aducanumab, aiming to improve amyloid-beta clearance in Alzheimer’s patients.
• Three participants were treated over six months, showing greater reduction in amyloid-beta levels in regions treated with ultrasound compared to untreated regions.
• The study was conducted under FDA approval and participants provided informed consent, ensuring ethical and regulatory compliance.
• Amyloid-beta levels were measured using fluorine-18 florbetaben PET, showing notable reductions in targeted brain regions.
• Cognitive tests and safety evaluations were conducted, revealing no significant adverse effects or cognitive decline during treatment.
• The trial was not sponsored by the manufacturers of the ultrasound device or aducanumab, ensuring unbiased results.
• Focused ultrasound was applied to one hemisphere, allowing comparison with untreated homologous regions in the other hemisphere.
• The study observed an average 32% reduction in amyloid-beta levels after 26 weeks in treated regions.
• No amyloid-related imaging abnormalities were observed, and the risk was mitigated by excluding APOE-ε4 genotype carriers.
• Cognitive worsening in one participant at 30 days follow-up warrants further investigation to determine its relation to treatment or disease progression.

According to the Alzheimer’s Association, Alzheimer’s disease is the 6th leading cause of death in the United States. Recent studies indicate that Alzheimer’s and other dementias will cost the nation $355 billion in 2021, with figures projected to rise to more than $1.1 trillion by 2050.

More on Alzheimer’s/Dementia